Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome: A Multicenter, Randomized Study
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Efficacy of symbiotics in patients with irritable bowel syndrome (IBS) remains unknown. METHODS: Patients were randomized to a prebiotic (n=135), or a symbiotic formulation containing Lactobacillus paracasei B21060 (Flortec, n=132). Primary efficacy was the responder rate for pain and global relief of symptoms in the overall population and in patients with predominant diarrhea (n=47). Post hoc time-trend analyses for changes within each treatment were carried out. RESULTS: Patients with absent/mild pain amounted to 54.7% in the symbiotic group and to 57.4% in the prebiotic group at treatment week 4, and to 53.9% and 53.4% at the end of treatment. Patients with amelioration of well-being were, respectively, 60.7% versus 61.7% at treatment week 4, and 63.3% versus 60.9% at the end of treatment. Within each treatment group, patients with absent/mild pain increased in the Flortec and the prebiotic group, but time trend analyses were significant only for Flortec (P=0.019). In IBS-predominant diarrhea, Flortec significantly reduced bowel movements, pain, and IBS scores. CONCLUSIONS: To improve pain and well-being, Flortec is encouraging in patients with diarrhea predominant IBS. To establish its efficacy for the majority of IBS patients, Flortec has to be compared with an inert placebo in future work.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With regard to synbiotics, there are some studies but their design is not sufficiently robust to draw any firm conclusions251–255 although the concept of combining a prebiotic and probiotic is theoretically attractive.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [251]
Citations
Cites
Dietary modulation of the human colonic microbiota: updating the concept of prebiotics
Gibson, G. R., Probert, H. M., Loo, J. V., Rastall, R. A., & Roberfroid, M. B. (2004) · Nutrition Research Reviews · doi:10.1079/nrr200479 · Cited by 2,536 · cited 1×
“As shown in human studies, supplementation with fructose-oligosaccharides leads to considerable changes in the composition of the fecal flora.(16,17) This would mean that in our study the placebo was not inert but acted as a prebiotic.”
ResultFunctional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Postinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Activation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833
Malinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699
Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis
D'Souza, A. L., Rajkumar, C., Cooke, J., & Bulpitt, C. J. (2002) · BMJ · doi:10.1136/bmj.324.7350.1361 · Cited by 664 · cited 1×
“Lactobacilli are considered to be safe for healthy and immunosuppressed individuals.(20,21) Twenty-five subjects in the symbiotic group and 30 in the placebo had symptoms worsened during the study, but only 5 and 4 subjects, respectively, withdrew from the study because of adverse effects.”
BackgroundSafety of Probiotics That Contain Lactobacilli or Bifidobacteria
Borriello, S. P., Hammes, W. P., Holzapfel, W., Marteau, P., Schrezenmeir, J., Vaara, M., & Valtonen, V. (2003) · Clinical Infectious Diseases · doi:10.1086/368080 · Cited by 551 · cited 1×
“Lactobacilli are considered to be safe for healthy and immunosuppressed individuals.(20,21) Twenty-five subjects in the symbiotic group and 30 in the placebo had symptoms worsened during the study, but only 5 and 4 subjects, respectively, withdrew from the study because of adverse effects.”
BackgroundDesign of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Onset and Disappearance of Gastrointestinal Symptoms and Functional Gastrointestinal Disorders
Talley, N. J., Weaver, A. L., Zinsmeister, A. R., & Melton, L. J. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116483 · Cited by 475 · cited 1×
“As shown in human studies, supplementation with fructose-oligosaccharides leads to considerable changes in the composition of the fecal flora.(16,17) This would mean that in our study the placebo was not inert but acted as a prebiotic.”
ResultMeta‐analysis: the effect of probiotic administration on antibiotic‐associated diarrhoea
Cremonini, F., Di Caro, S., Nista, E. C., Bartolozzi, F., Capelli, G., Gasbarrini, G., & Gasbarrini, A. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01318.x · Cited by 384
Cited by
Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645
Preidis, G. A., & Versalovic, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.072 · Cited by 485
Diagnosis and Treatment of Irritable Bowel Syndrome: A Review
Camilleri, M. (2021) · JAMA · doi:10.1001/jama.2020.22532 · Cited by 362
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320
Therapeutical use of probiotic formulations in clinical practice
Iannitti, T., & Palmieri, B. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2010.05.004 · Cited by 260
“78 tested the efficacy of symbiotics in patients with D-IBS. Patients were randomized to a prebiotic (n ¼ 135), or a symbiotic formulation containing Lactobacillus paracasei B21060 (Flortec, n ¼ 132).”
BackgroundPrebiotics and probiotics; modifying and mining the microbiota
Quigley, E. M. M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.004 · Cited by 238
Clarke, G., Cryan, J. F., Dinan, T. G., & Quigley, E. M. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04965.x · Cited by 216
Simon, E., Călinoiu, L. F., Mitrea, L., & Vodnar, D. C. (2021) · Nutrients · doi:10.3390/nu13062112 · Cited by 213
“Reference Study Type Intervention Number ofSubjects (n) Subjects Metrics Inclusion Criteria Trial Duration Beneficial Effects Tsuchiya et al., 2004 [122] Single-blind, preliminary, controlled trial 10 mL of SCM-III synbiotic consisting of 1.25 × 105 cfu/mL L. acidophilus, 1.3 × 108 cfu/mL L. helveticus, 4.95 × 108 cfu…”
MethodInfluentialThe Role of Diet in Symptoms of Irritable Bowel Syndrome in Adults: A Narrative Review
Heizer, W. D., Southern, S., & McGovern, S. (2009) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2009.04.012 · Cited by 209
Martinez, R. C. R., Bedani, R., & Saad, S. M. I. (2015) · British Journal of Nutrition · doi:10.1017/s0007114515003864 · Cited by 203
Prebiotics and Probiotics: Their Role in the Management of Gastrointestinal Disorders in Adults
Quigley, E. M. M. (2012) · Nutrition in Clinical Practice · doi:10.1177/0884533611423926 · Cited by 175
Manipulation of the Microbiota for Treatment of IBS and IBD—Challenges and Controversies
Shanahan, F., & Quigley, E. M. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.050 · Cited by 172
“It therefore might be unrealistic to expect a single agent to cure all symptoms of IBS.”
BackgroundInfluentialDuPont, H. L. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12728 · Cited by 171
“otic [viable lyophilised Lactobacillus paracasei B21060 (5 9 10(9) colony-forming units)] and prebiotic [xylooligosaccharides (700 mg) and glutamine (500 mg)] or a control formulation (n = 135) was administered for 12 weeks in patients with IBS based on Rome II criteria.(52) The synbiotic preparation alleviated IBS sy…”
MethodThe microbiota-gut-brain axis in functional gastrointestinal disorders
De Palma, G., Collins, S. M., & Bercik, P. (2014) · Gut Microbes · doi:10.4161/gmic.29417 · Cited by 157
Probiotics: health benefits in the mouth.
Stamatova, I., & Meurman, J. H. (2009) · PubMed · Cited by 201
Sisson, G., Ayis, S., Sherwood, R. A., & Bjarnason, I. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12787 · Cited by 147
Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate
Gallo, A., Passaro, G., Gasbarrini, A., Landolfi, R., & Montalto, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7186 · Cited by 119
Antibiotic resistance determinants in the interplay between food and gut microbiota
Devirgiliis, C., Barile, S., & Perozzi, G. (2011) · Genes & Nutrition · doi:10.1007/s12263-011-0226-x · Cited by 105
“Together with the closely related species L. casei, L. rhamnosus, and L. zeae, it is also one of the most common bacterial species employed as probiotic additives in the food industry ( Andriulli et al. 2008; Chouraqui et al. 2008).”
BackgroundHaller, D., Antoine, J., Bengmark, S., Enck, P., Rijkers, G. T., & Lenoir‐Wijnkoop, I. (2010) · Journal of Nutrition · doi:10.3945/jn.109.113746 · Cited by 114
Systemic effects of gut microbiota and its relationship with disease and modulation
Ho, J. T., Chan, G. C., & Li, J. C. (2015) · BMC Immunology · doi:10.1186/s12865-015-0083-2 · Cited by 93
“There have also been a few clinical trials that have tried to alleviate irritable bowel syndrome (IBS) with synbiotics, and these trials have shown some promise [29,33].”
BackgroundComunian, R., Daga, E., Dupré, I., Paba, A., Devirgiliis, C., Piccioni, V., Perozzi, G., Zonenschain, D., Rebecchi, A., Morelli, L., et al. (2009) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2009.11.018 · Cited by 103
“Although its probiotic functions have rendered it a common food additive (Andriulli et al, 2008; Chouraqui et al., 2008), recent reports have pointed to a possible pathogenic relevance of several Lactobacillus species, including L. paracasei (Cannon et al., 2005).”
BackgroundThe enteric microbiota in the pathogenesis and management of constipation
Quigley, E. M. M. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.01.003 · Cited by 93
Lombardi, V. C., Meirleir, K. L. D., Subramanian, K., Nourani, S. M., Dagda, R. K., Delaney, S. L., & Palotás, A. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.04.004 · Cited by 101
Synbiotics for Improved Human Health: Recent Developments, Challenges, and Opportunities
Krumbeck, J. A., Walter, J., & Hutkins, R. W. (2018) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-030117-012757 · Cited by 84
“…treat the various diseases described above, but these are not included in this discussion due to their absence of suitable or appropriate controls (Andriulli et al. 2008, Basturk et al. 2016, Colecchia et al. 2006, Dughera et al. 2007, Fujimori et al. 2007, Rossi et al. 2015), very low patient…”
BackgroundModulation of the gut microbiota: a focus on treatments for irritable bowel syndrome
Harris, L. A., & Baffy, N. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1383819 · Cited by 83
“Synbiotics Synbiotics contain a mixture of prebiotics and probiotics [63].”
BackgroundIrritable bowel syndrome: Role of food in pathogenesis and management
Morcos, A. I., Dinan, T. G., & Quigley, E. M. M. (2009) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2009.00392.x · Cited by 100
Bogovič Matijašić, B., Obermajer, T., Lipoglavšek, L., Sernel, T., Locatelli, I., Kos, M., Šmid, A., & Rogelj, I. (2016) · Journal of Dairy Science · doi:10.3168/jds.2015-10743 · Cited by 76
“…few reports on the effects of synbiotics including fermented milk-based and pharmaceutical formulations on the IBS patients (Tsuchiya et al., 2004; Andriulli et al., 2008; Cappello et al., 2013), but none of these studies was reported to be randomized double-blind, placebo-controlled, and…”
BackgroundProbiotics, prebiotics and the gastrointestinal tract in health and disease
Vitetta, L., Briskey, D. R., Alford, H., Hall, S., & Coulson, S. (2014) · Inflammopharmacology · doi:10.1007/s10787-014-0201-4 · Cited by 81
Quigley, E. M. M. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.12.009 · Cited by 67
Bonfrate, L., Tack, J., Grattagliano, I., Cuomo, R., & Portincasa, P. (2013) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2013.799220 · Cited by 67
“[129] Andriulli A, Neri M, Loguercio C, Terreni N, Merla A, Cardarella MP, et al.”
BackgroundCappello, C., Tremolaterra, F., Pascariello, A., Ciacci, C., & Iovino, P. (2012) · International Journal of Colorectal Disease · doi:10.1007/s00384-012-1552-1 · Cited by 71
“The rationale for choosing this symbiotic mixture for our study was based on several reasons: the product is already available on the market, has a record of safe human consumption and to our knowledge there is only one other double-blinded RCT on a single-strain symbiotic mixture which was performed regarding IBS [15…”
BackgroundGargari, G., Mantegazza, G., Cremon, C., Taverniti, V., Valenza, A., Barbaro, M. R., Marasco, G., Duncan, R., Fiore, W., Ferrari, R., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2023.2298246 · Cited by 76
“12,13 Although specific microbial strains have shown promising results, 14 meta-analyses have reported inconsistent findings concerning the efficacy of pro-biotics for various IBS outcome measures, potentially due to wide variability among the probiotic formulations considered [differences in…”
Wu, Y., Li, Y., Zheng, Q., & Li, L. (2024) · Nutrients · doi:10.3390/nu16132114 · Cited by 81
Treating irritable bowel syndrome with probiotics: the evidence
Parkes, G. C., Sanderson, J. D., & Whelan, K. (2010) · Proceedings of the Nutrition Society · doi:10.1017/s002966511000011x · Cited by 57
“A symbiotic preparation, Flortec1 (Bracco spA, Milan, Italy), that contains a combination of prebiotic (xylooligosaccharide) and probiotic (Lactobacillus paracasei B21060) has been used in a large (n 267) multi-centre trial, with Flortec1 as the treatment arm and xylo-oligosaccharide alone as the control arm((58)).”
BackgroundMethodDevirgiliis, C., Coppola, D., Barile, S., Colonna, B., & Perozzi, G. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00589-09 · Cited by 57
“Moreover, due to its probiotic functions, it is also employed as food additive (3, 5).”
BackgroundWhat’s bugging your teen?—The microbiota and adolescent mental health
McVey Neufeld, K.-A., Luczynski, P., Seira Oriach, C., Dinan, T. G., & Cryan, J. F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.005 · Cited by 56
“…to have ameliorative effects in patients suffering from IBS (Niedzielin et al., 2001; Bauserman and Michail, 2005; Whorwell et al., 2006; Andriulli et al., 2008; Enck et al., 2008; Enck et al., 2009; Hun, 2009; Williams et al., 2009; Francavilla et al., 2010; Guglielmetti et al., 2011;…”
Oh, J. H., Jang, Y. S., Kang, D., Chang, D. K., & Min, Y. W. (2019) · Nutrients · doi:10.3390/nu11122887 · Cited by 45
“paracase [26] have been conducted, and these organisms have shown effects on IBS symptoms.”
BackgroundHigh-fibre diet andLactobacillus paracasei B21060in symptomatic uncomplicated diverticular disease
Lahner, E., Esposito, G., Zullo, A., Hassan, C., Cannaviello, C., Paolo, M. C. D., Pallotta, L., Garbagna, N., Grossi, E., & Annibale, B. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i41.5918 · Cited by 49
The Rationale and Clinical Effectiveness of Probiotics in Irritable Bowel Syndrome
Ringel, Y., & Ringel-Kulka, T. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31822d32d3 · Cited by 44
Xie, P., Luo, M., Deng, X., Fan, J., & Xiong, L. (2023) · Nutrients · doi:10.3390/nu15173856 · Cited by 50
Yoon, J. Y., Cha, J. M., Hong, S. S., Kim, H. K., Kwak, M. S., Jeon, J. W., & Shin, H. P. (2019) · Medicine · doi:10.1097/md.0000000000016601 · Cited by 46
“Lactobacillus paracasei, which is one of the representative Lactobacillus strains producing large amounts of EPS,([16]) has demonstrated positive effects on health and disease in many clinical trials, such as improvement of symptoms in gastroenteritis, colonic diverticulitis,([21,22]) or irritable bowel syndrome([23])…”
BackgroundExploring lactic acid bacteria in food, human health, and agriculture
Murata, R., Shim, Y. Y., Kim, Y. J., Reaney, M. J. T., & Tse, T. J. (2025) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2025.2493236 · Cited by 52
“For example, B. bifidum MIMBb75 (Guglielmetti et al. 2011), L. acidophilus -SDC (Sinn et al. 2008), Lcb. para-casei B2106 (Andriulli et al. 2008), and Lp. plantarum 299 V (Niedzielin, Kordecki, and Birkenfeld 2001) have demonstrated reductions in abdominal pain/discomfort associated with IBS.”
Adiponectin Role in Neurodegenerative Diseases: Focus on Nutrition Review
Polito, R., Meo, I. D., Barbieri, M., Daniele, A., Paolisso, G., & Rizzo, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239255 · Cited by 44
Corbitt, M., Campagnolo, N., Staines, D., & Marshall‐Gradisnik, S. (2018) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-018-9397-8 · Cited by 39
Probiotics use to treat irritable bowel syndrome
Hosseini, A., Nikfar, S., & Abdollahi, M. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707179 · Cited by 35
Šmid, A., Strniša, L., Bajc, K., Vujić-Podlipec, D., Matijašić, B. B., & Rogelj, I. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.04.031 · Cited by 41
Mandarino, F. V., Sinagra, E., Barchi, A., Verga, M. C., Brinch, D., Raimondo, D., & Danese, S. (2023) · Microorganisms · doi:10.3390/microorganisms11051122 · Cited by 31
Jones, R. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00009-4 · Cited by 36
The Shortcomings of Clinical Trials Assessing the Efficacy of Probiotics in Irritable Bowel Syndrome
Rogers, N. J., & Mousa, S. A. (2012) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2011.0015 · Cited by 28
Oh, J. H., Jang, Y. S., Kang, D., Kim, H. S., Kim, E.-J., Park, S.-Y., Kim, C., Min, Y. W., & Chang, D. K. (2022) · Gut and Liver · doi:10.5009/gnl210478 · Cited by 29
“16 In contrast, in a trial with 132 patients with IBS, Lactobacillus, Bifidobacterium, Streptococcus, and prebiotic fructo-oligosaccharides showed no beneficial effects over placebo during a 2-week treatment.”
Grossi, E., Buresta, R., Abbiati, R. A., & Cerutti, R. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181e103f4 · Cited by 25
“Flortec treatment has been shown to be effective in relieving symptoms associated with diarrhea of the irritable bowel syndrome subtype and in shortening its duration.(5) The objective of this study was to assess its potential role in acute diarrhea in primary care and to verify whether the administration of the L.”
BackgroundSelf-citationThe Future of Probiotics for Disorders of the Brain-Gut Axis
Quigley, E. M. M., & Shanahan, F. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-0897-4_19 · Cited by 20
Matsuura, N., Kanayama, M., Watanabe, Y., Yamada, H., Lili, L., & Torii, A. (2024) · Nutrients · doi:10.3390/nu16193333 · Cited by 20
“However, further studies are necessary to comprehensively evaluate the effect of these supplements.”
BackgroundAlmansa, C., Agrawal, A. K., & Houghton, L. A. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.9 · Cited by 14
In Vitro Screening and Evaluation of Synbiotics
Skalkam, M. L., Wiese, M., Nielsen, D. S., & van Zanten, G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00033-2 · Cited by 18
Prebiotics for irritable bowel syndrome
Quigley, E. M. M. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.46 · Cited by 9
Probiotics, with special emphasis on their role in the management of irritable bowel syndrome
Stevenson, C., & Blaauw, R. (2011) · South African Journal of Clinical Nutrition · doi:10.1080/16070658.2011.11734353 · Cited by 7
“lactis in IBS have failed to demonstrate benefit, again often in part as a result of a high placebo response.(63,81) A French multicentre trial of B.”
BackgroundWhy Use Nutraceutical Strategies for the Irritable Bowel Syndrome?
di Michele, F. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210917115255 · Cited by 5
The Role of Probiotics in the Treatment of Irritable Bowel Syndrome
Parkes, G. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374938-3.00030-x · Cited by 6
Probiotics and prebiotics, including fibers and medicinal foods
Jana, T., Acker, B. W., & Cash, B. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813037-7.00042-x · Cited by 4
de Figueiredo, F. C., & Neto, P. D. O. (2022) · Clean Energy Production Technologies · doi:10.1007/978-981-16-3682-0_10 · Cited by 7
Biniszewska, O., Jacenik, D., Tarasiuk, A., & Fichna, J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2366993 · Cited by 5
“A study reported by Andriulli et al. [71] aimed to evaluate the efficacy of symbiotics in the treatment of IBS.”
BackgroundMethodClinical Insights: Probiotics, Prebiotics and Gut Health
Floch, M. H., & Kim, A. S. (2014) · doi:10.2217/9781780843360 · Cited by 3
Symbiotics, Probiotics, and Fiber Diet in Diverticular Disease
Lahner, E., & Annibale, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00035-6 · Cited by 1
Lactobacillus paracasei: probiotic properties and clinical efficacy
Новикова, В. П., & Кравцова, К. А. (2024) · Russian Medical Inquiry · doi:10.32364/2587-6821-2024-8-5-4 · Cited by 2
Bucci, C., Santonicola, A., & Iovino, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00040-x · Cited by 1
Effect of Synbiotic-Assisted Modulation of Gastrointestinal Microbiota on Human Health
Khedkar, C. D., Kalyankar, S. D., Patel, A. R., & Khedkar, C. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809762-5.00018-8 · Cited by 2
[Irritable bowel syndrome: a functional disorder?].
Man, F., & Fernández, L. M. B. (2013) · PubMed
Probiotics, with special emphasis on their role in the management of irritable bowel syndrome
Stevenson, C., & Blaauw, R. (2012) · Pharmacy management
Use of probiotics in irritable bowel syndrome
Quigley, E. M. M. (2014) · doi:10.2217/ebo.13.517
EFSA Panel on Dietetic Products, N. A. A. (. (2010) · EFSA Journal · doi:10.2903/j.efsa.2010.1804
An Update on Clinical Trials on Synbiotics
Yanadaiah, P., Babu, M. R., Dureja, H., Kumbhar, P., Disouza, J., Gupta, G., Dua, K., & Singh, S. K. (2024) · Springer eBooks · doi:10.1007/978-981-99-5575-6_25
Metadata
- Authors
- Andriulli, A., Neri, M., Loguercio, C., Terreni, N., Merla, A., Cardarella, M. P., Federico, A., Chilovi, F., Milandri, G. L., De Bona, M., Cavenati, S., Gullini, S., Abbiati, R., Garbagna, N., Cerutti, R., & Grossi, E.
- Affiliations
- Casa Sollievo della Sofferenza (IT)
- University of Chieti-Pescara (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Ospedale Valduce (IT)
- Ospedale di Bolzano (IT)
- Ospedale “M. Bufalini” di Cesena (IT)
- Corresponding author
- Andriulli, Angelo
- Merla, Antonio
- Cavenati, Sergio
- ORCID
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2008-09
- Volume
- 42
- Issue
- Supplement 3
- Pages
- S218-S223
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2031153328
- Cited by
- 75
- References
- 25
- Citations by year
- 2025: 1 · 2024: 6 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 5 · 2014: 9 · 2013: 2 · 2012: 8
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, symbiotics, prebiotics, Lactobacillus paracasei, abdominal pain, well-being, defecation, probiotics
- MeSH terms
- Adult, Double-Blind Method, Drug Synergism, Female, Glutamine, Humans, Lactobacillus, Male, Middle Aged, Oligosaccharides, Treatment Outcome, Probiotics, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.